Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of ch...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Kater, Arnon P., van Oers, Marinus H.J., van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F.M., Schipperus, Martin, Chamuleau, Martine E.D., Nijland, Marcel, Doorduijn, Jeanette K., Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Schaafsma, Martijn R., Dobber, Johan A., Kersting, Sabina, Levin, Mark-David
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312018/
https://ncbi.nlm.nih.gov/pubmed/30115656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.193854
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares